{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T09:41:11Z","timestamp":1684230071166},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"575","license":[{"start":{"date-parts":[[1973,9,1]],"date-time":"1973-09-01T00:00:00Z","timestamp":115689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1973,9,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>A case report of a patient with agranulocytosis associated with sulphasalazine therapy is described. Recovery followed supportive therapy and withdrawal of the drug. Investigations including tests for leucocyte antibodies, the presence of which might have suggested an immunological cause for the drug reaction, were negative; an acetylation study, however, characterized the patient as a \u2018slow\u2019 acetylator phenotype, suggesting that the drug reaction was more likely to have been toxic in nature. It is suggested that acetylation studies be performed in patients who have previously shown serious side effects to sulphasalazine to assess the incidence of \u2018slow\u2019 acetylators.<\/jats:p>","DOI":"10.1136\/pgmj.49.575.669","type":"journal-article","created":{"date-parts":[[2008,12,29]],"date-time":"2008-12-29T20:31:39Z","timestamp":1230582699000},"page":"669-672","source":"Crossref","is-referenced-by-count":5,"title":["Agranulocytosis associated with sulphasalazine therapy"],"prefix":"10.1093","volume":"49","author":[{"given":"P","family":"Cochrane","sequence":"first","affiliation":[{"name":"Walton Hospital , Liverpool"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Atkins","sequence":"additional","affiliation":[{"name":"Walton Hospital , Liverpool"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Ehsanullah","sequence":"additional","affiliation":[{"name":"Walton Hospital , Liverpool"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1973,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000202343","article-title":"The occurrence of Heinz-bodies during Azulfidine treatment of ulcerative colitis","volume":"100","author":"BOTTINGER, L.E.; ENGSTEDT, L.; LAGERCRANTZ, R.; NYBERG, A.","year":"1963","unstructured":"BOTTINGER, L.E., ENGSTEDT, L., LAGERCRANTZ, R. & NYBERG, A. (1963) The occurrence of Heinz-bodies during Azulfidine treatment of ulcerative colitis. Gastroenterologia, 100, 33.","journal-title":"Gastroenterologia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00007611-196804000-00005","article-title":"Adverse reactions to salicylazosulfapyridene (Azulfidine) in the treatment of ulcerative colitis","volume":"61","author":"COLLINS, J.R.","year":"1968","unstructured":"COLLINS, J.R. (1968) Adverse reactions to salicylazosulfapyridene (Azulfidine) in the treatment of ulcerative colitis. Journal of the Southern Medical Association, 61, 354.","journal-title":"Journal of the Southern Medical Association"},{"key":"ref_3","first-page":"380","article-title":"In: Clinical Haematology in Medical Practice","author":"GRUCHY, D.E.; C, G.","year":"1970","unstructured":"DE GRUCHY, G.C. (1970) In: Clinical Haematology in Medical Practice, 3rd edn, p. 380. Blackwell Scientific Publications, Oxford.","edition":"3rd edn"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/archinte.1958.00260140076012","article-title":"Studies of the bone marrow in immunological granulocytopenia following administration of salicylazosulfapyridene","volume":"101","author":"EVANS, R.S.; FORD, W.P.","year":"1958","unstructured":"EVANS, R.S. & FORD, W.P. (1958) Studies of the bone marrow in immunological granulocytopenia following administration of salicylazosulfapyridene. Archives of Internal Medicine, 101, 244.","journal-title":"Archives of Internal Medicine"},{"key":"ref_5","first-page":"394","article-title":"Human acetylation polymorphism","volume":"63","author":"EVANS, D.A.P.; WHITE, T.A.","year":"1964","unstructured":"EVANS, D.A.P. & WHITE, T.A. (1964) Human acetylation polymorphism. Journal of Laboratory and Clinical Medicine, 63, 394.","journal-title":"Journal of Laboratory and Clinical Medicine"},{"key":"ref_6","first-page":"71","article-title":"Hemolytic anemia secondary to salicylazosulfapyridene therapy","volume":"190","author":"GARDNER, M.D.; BARGEN, J.A.","year":"1964","unstructured":"GARDNER, M.D. & BARGEN, J.A. (1964) Hemolytic anemia secondary to salicylazosulfapyridene therapy. Journal of the American Medical Association, 190, 71.","journal-title":"Journal of the American Medical Association"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/gut.1.3.217","article-title":"An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis","volume":"1","author":"LENNARD-JONES, J.E.; LONGMORE, A.J.; NEWELL, A.C.; WILSON, C.W.E.; JoNEs, F.A.","year":"1960","unstructured":"LENNARD-JONES, J.E., LONGMORE, A.J., NEWELL, A.C., WILSON, C.W.E. & JoNEs, F.A. (1960) An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut, 1, 217.","journal-title":"Gut"},{"key":"ref_8","first-page":"185","article-title":"Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis","volume":"1","author":"MISIEWICZ, J.J.; LENNARD-JONES, J.E.; CONNELL, A.M.; BARON, J.H.; JONES, F.A.","year":"1965","unstructured":"MISIEWICZ, J.J., LENNARD-JONES, J.E., CONNELL, A.M., BARON, J.H. & JONES, F.A. (1965) Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet, 1, 185.","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/bmj.3.5825.506","article-title":"Simplified method for determining acetylator phenotype","volume":"3","author":"SCHROEDER, H.","year":"1972","unstructured":"SCHROEDER, H. (1972) Simplified method for determining acetylator phenotype. British Medical Journal, 3, 506.","journal-title":"British Medical Journal"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/gut.13.4.278","article-title":"Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects","volume":"13","author":"SCHROEDER, H.; EVANS, D.A.P.","year":"1972","unstructured":"SCHROEDER, H. & EVANS, D.A.P. (1972) Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut, 13, 278.","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.0954-6820.1942.tb06841.x","article-title":"Salazopyrin, a new sulfanilimide preparation. A. Therapeutic results in aneumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilimide preparations","volume":"110","author":"SVARTZ, N.","year":"1942","unstructured":"SVARTZ, N. (1942) Salazopyrin, a new sulfanilimide preparation. A. Therapeutic results in aneumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilimide preparations. Acta medica scandinavica, 110, 577.","journal-title":"Acta medica scandinavica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/204998b0","article-title":"Microdroplet assay of human serum cytotoxins","volume":"204","author":"TERASUKI, P.I.; MCCLENNAND, J.D.","year":"1964","unstructured":"TERASUKI, P.I. & MCCLENNAND, J.D. (1964) Microdroplet assay of human serum cytotoxins. Nature, 204, 998.","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0140-6736(63)92048-8","article-title":"Agranulocytosis associated with sulphasalazine","volume":"i,","author":"THIRKETTLE, J.L.; GOUGH, K.R.; READ, A.E.","year":"1963","unstructured":"THIRKETTLE, J.L., GOUGH, K.R. & READ, A.E. (1963) Agranulocytosis associated with sulphasalazine ('Salazopyrin') therapy. Lancet, i, 1395.","journal-title":"('Salazopyrin') therapy. Lancet"},{"key":"ref_14","first-page":"1","article-title":"In: Leukocyte Antigens and Antibodies","volume-title":"6. Grune and Stratton, New York and","author":"WALFORD, R.L.","year":"1960","unstructured":"WALFORD, R.L. (1960) In: Leukocyte Antigens and Antibodies, p. 1 6. Grune and Stratton, New York and London."}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/49\/575\/669\/50253705\/postgradmedj-49-669.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/49\/575\/669\/50253705\/postgradmedj-49-669.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T09:00:40Z","timestamp":1684227640000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/49\/575\/669\/7064790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1973,9,1]]},"references-count":14,"journal-issue":{"issue":"575","published-online":{"date-parts":[[1973,9,1]]},"published-print":{"date-parts":[[1973,9,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.49.575.669","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1973,9]]},"published":{"date-parts":[[1973,9,1]]}}}